These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 25823514)

  • 1. Revisiting the Serotonin Hypothesis: Implications for Major Depressive Disorders.
    Fakhoury M
    Mol Neurobiol; 2016 Jul; 53(5):2778-2786. PubMed ID: 25823514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 5-HT
    Tiger M; Varnäs K; Okubo Y; Lundberg J
    Psychopharmacology (Berl); 2018 May; 235(5):1317-1334. PubMed ID: 29546551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.
    Sanchez C; Asin KE; Artigas F
    Pharmacol Ther; 2015 Jan; 145():43-57. PubMed ID: 25016186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin receptors involved in antidepressant effects.
    Artigas F
    Pharmacol Ther; 2013 Jan; 137(1):119-31. PubMed ID: 23022360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of serotonin neurotransmission in knockout mice: implications for major depression.
    Domínguez-López S; Howell R; Gobbi G
    Rev Neurosci; 2012; 23(4):429-43. PubMed ID: 23089640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants.
    Pehrson AL; Sanchez C
    Drug Des Devel Ther; 2015; 9():603-24. PubMed ID: 25653499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ubiquitination of serotonin transporter in lymphoblasts derived from fluvoxamine-resistant depression patients.
    Mouri A; Ikeda M; Koseki T; Iwata N; Nabeshima T
    Neurosci Lett; 2016 Mar; 617():22-6. PubMed ID: 26845564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia.
    López-Figueroa AL; Norton CS; López-Figueroa MO; Armellini-Dodel D; Burke S; Akil H; López JF; Watson SJ
    Biol Psychiatry; 2004 Feb; 55(3):225-33. PubMed ID: 14744462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study.
    Parsey RV; Oquendo MA; Ogden RT; Olvet DM; Simpson N; Huang YY; Van Heertum RL; Arango V; Mann JJ
    Biol Psychiatry; 2006 Jan; 59(2):106-13. PubMed ID: 16154547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant mouse models and antidepressant drug research: focus on serotonin and brain-derived neurotrophic factor.
    Gardier AM
    Behav Pharmacol; 2009 Feb; 20(1):18-32. PubMed ID: 19179848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Selectivity and Antidepressant Activity of Serotonin 1A Receptor Ligands.
    Chilmonczyk Z; Bojarski AJ; Pilc A; Sylte I
    Int J Mol Sci; 2015 Aug; 16(8):18474-506. PubMed ID: 26262615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin receptors in depression: from A to B.
    Nautiyal KM; Hen R
    F1000Res; 2017; 6():123. PubMed ID: 28232871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developments in the field of antidepressants, where do we go now?
    Artigas F
    Eur Neuropsychopharmacol; 2015 May; 25(5):657-70. PubMed ID: 23706576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder.
    Lin E; Chen PS; Chang HH; Gean PW; Tsai HC; Yang YK; Lu RB
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1167-72. PubMed ID: 19560507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapeutic strategies in major depression: focus on RNAi and ketamine.
    Bortolozzi A; Celada P; Artigas F
    Curr Pharm Des; 2014; 20(23):3848-60. PubMed ID: 24180396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulating the serotonin system in the treatment of major depressive disorder.
    Morrissette DA; Stahl SM
    CNS Spectr; 2014 Dec; 19 Suppl 1():57-67; quiz 54-7, 68. PubMed ID: 25544378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disproportionate Reduction of Serotonin Transporter May Predict the Response and Adherence to Antidepressants in Patients with Major Depressive Disorder: A Positron Emission Tomography Study with 4-[18F]-ADAM.
    Yeh YW; Ho PS; Kuo SC; Chen CY; Liang CS; Yen CH; Huang CC; Ma KH; Shiue CY; Huang WS; Shyu JF; Wan FJ; Lu RB; Huang SY
    Int J Neuropsychopharmacol; 2015 Jan; 18(7):pyu120. PubMed ID: 25568284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational site-directed pharmacotherapy for major depressive disorder.
    Blier P
    Int J Neuropsychopharmacol; 2014 Jul; 17(7):997-1008. PubMed ID: 23745670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The P11, tPA/plasminogen system and brain-derived neurotrophic factor: Implications for the pathogenesis of major depression and the therapeutic mechanism of antidepressants.
    Tsai SJ
    Med Hypotheses; 2007; 68(1):180-3. PubMed ID: 16890384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.